Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue and revisiting drugs with focus on brain tumor penetration may yield surprises.
from Cancer via ola Kala on Inoreader http://ift.tt/2iRpvTE
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου